news
White House review for next FDA Commissioner is nearing decision
The White House is in the final stages of reviewing candidates to lead the FDA, a decision that could come soon. This appointment is critical for the health and wellness industry, particularly for policies around supplements, GLP-1s, and other emerging biotech products.
The White House is in the final stages of reviewing candidates to lead the FDA, a decision that could come soon. This appointment is critical for the health and wellness industry, particularly for policies around supplements, GLP-1s, and other emerging biotech products.
The architecture take
Okay, so the FDA is about to get a new boss, and this isn't just bureaucratic reshuffling. The person leading the FDA sets the tone for everything from GLP-1 access to how supplements are regulated, and even the future of psychedelics and peptides. Think about it: this one person can slow down or speed up innovation, make or break entire categories of wellness products, and ultimately decide what ends up in your body and how it's marketed to you. Their stance on 'claims' vs. 'efficacy' directly impacts what you can and can't buy, and what companies can even promise about it. Watch for signals on their prior opinions when the announcement drops – it's a huge tell for what's about to come down the pike for consumers and the brands targeting them.